Previous Article | Next Article ![]()
Infection and Immunity, December 2001, p. 7753-7759, Vol. 69, No. 12
Department of Medical Microbiology and
Immunology, University of South Florida College of Medicine, Tampa,
Florida 33612,1 and Department of
Histology and Cell Biology, Nagasaki University School of Medicine,
Nagasaki 852-8523, Japan2
Received 16 May 2001/Returned for modification 3 July 2001/Accepted 24 August 2001
The obligate intracellular pathogen Chlamydia
(Chlamydophila) pneumoniae is known to be associated with some
chronic inflammatory diseases, such as atherosclerosis. Interaction
between C. pneumoniae and immune cells is important in
the development of such diseases. However, susceptibility of immune
cells, particularly lymphocytes, to C. pneumoniae
infection has not been reported, even though lymphocytes play a pivotal
role in the development of the diseases caused by this bacterium. In
this regard, we examined the susceptibility of lymphocytes to C.
pneumoniae infection in vitro. The results demonstrated that
human peripheral blood lymphocytes as well as mouse spleen lymphocytes
could be infected with C. pneumoniae. Furthermore,
purified T lymphocytes as well as established T-lymphocyte cell line
cells showed an obvious susceptibility to C. pneumoniae infection, indicating that T cells could be one of the host cells for
this bacterial infection. These findings reveal a new infection site
for C. pneumoniae, i.e., lymphocytes.
Chlamydia (Chlamydophila)
pneumoniae is an obligate intracellular bacterium which causes a
variety of respiratory illnesses, including community-acquired
pneumonia, bronchitis, pharyngitis, and sinusitis (25).
Current studies also indicate the possible involvement of C. pneumoniae in chronic inflammatory as well as other diseases, such
as asthma (10), arthritis (8), and
atherosclerosis (23), besides respiratory illness.
However, even though there are a large number of reports relating
C. pneumoniae infection and certain chronic inflammatory
diseases, the mechanisms for development of such diseases by
Chlamydia infection is not clear. In the case of
atherosclerosis, for instance, how Chlamydia organisms reach
the intima, which is the main site of atherosclerosis, and how
Chlamydia spp. are involved in the chronic inflammatory
reaction characterized in atherosclerosis are not well understood. It
is known that lymphocytes always play a central role in the development of chronic inflammatory diseases by their diverse functions. In this
regard, a recent study by Kaul et al. (18) showed an
interesting finding indicating that Chlamydia DNA could be
recovered from CD3+ peripheral blood leukocytes
obtained from the patients attending a cardiology clinic. This finding
suggests the possibility that lymphocytes may be a host cell for
C. pneumoniae.
Although C. pneumoniae is known to preferentially infect the
epithelial tissue of the respiratory tract, this bacterium can also
multiply in vitro in monocytes/macrophages, endothelial cells, and
aortic smooth muscle cells (1, 3, 4, 9, 17, 26). However,
there are no reports regarding experimental in vitro infection of
lymphocytes with C. pneumoniae which demonstrate that
lymphocytes can be a host cell. The study reported here demonstrates that lymphocytes, particularly T lymphocytes, can be infected with
C. pneumoniae and support the growth of this bacterium in vitro. These findings may reveal a possible new Chlamydia
infection pathway, i.e., lymphocytes.
Bacterial strain, propagation, and purification.
C. pneumoniae (CM-1, ATCC VR-1360) was obtained from the
American Type Culture Collection, Manassas, Va., and propagated in HEp-2 cell cultures as described (22). Chlamydial
elementary bodies (EBs) were purified by density gradient
centrifugation with Percoll (Sigma Chemical, St. Louis, Mo.)
(13). Purified EBs were suspended in
sucrose-phosphate-glutamic acid (0.2 M sucrose, 3.8 mM
KH2PO4, 6.7 mM
Na2HPO4, 5 mM
L-glutamic acid) buffer (pH 7.4) and stored in
small aliquots at Lymphocytes.
Human peripheral blood lymphocytes were
isolated from buffy coats provided by the Florida Blood Services, St.
Petersburg, Fla., by density gradient centrifugation with
Histopaque-1077 (Sigma). The resulting peripheral blood mononuclear
cells were washed three times with Hanks' balanced salt solution
(HBSS) and suspended in RPMI 1640 medium containing 10%
heat-inactivated human AB blood type serum (Sigma). The peripheral
blood mononuclear cell suspensions were then dispensed in tissue
culture flasks and incubated for 2 h at 37°C in 5%
CO2 to adhere out the monocytes. After
incubation, nonadherent cells were collected, washed with HBSS, and
resuspended in RPMI 1640 medium containing 10% AB serum. Cytocentrifuged preparations of the resulting lymphocyte fractions stained with Giemsa showed greater than 95% lymphocytes by morphology.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.12.7753-7759.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Chlamydia pneumoniae Infects and
Multiplies in Lymphocytes In Vitro
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C until used. Inclusion forming units (IFUs)
of the Chlamydia preparation were determined by counting
Chlamydia inclusions in HEp-2 cells as described elsewhere (29).
T-lymphocyte cell line. The human T-lymphocyte cell line Molt 3 was kindly provided by R. Widen, Tampa General Hospital, Tampa, Fla. Cultures of the cell line (106 cells) were infected with either viable bacteria (107 IFUs) or UV-treated bacteria (107 organisms; prepared by placing cultures 1.0-cm distance under UV light for 15 min) or cultured without bacteria in 2.0 ml of RPMI 1640 medium containing 10% heat-inactivated FCS and antibiotics (gentamicin, 10 µg/ml; vancomycin, 10 µg/ml; and amphotericin B, 1 µg/ml) for 3 h at 37°C in 5% CO2 with gentle shaking. After two washes with HBSS by centrifugation, the cultures were resuspended in 10 ml of medium and then incubated for 72 h in the presence of cycloheximide (1 µg/ml; Sigma).
Infection of lymphocytes. Lymphocyte suspensions in RPMI 1640 medium supplemented with either 10% AB serum for human lymphocytes or 10% FCS for mouse lymphocytes and 2 mM L-glutamine were dispensed in six-well tissue culture plates at 2 × 106 cells/3.0 ml/well. The lymphocyte cultures were then infected with 108 IFUs of EBs/well by gentle shaking with a shaker for 2 h at 37°C. After infection, the cells were washed with HBSS two times by centrifugation and resuspended in RPMI 1640 medium containing cycloheximide (0.5 µg/ml) and either 10% AB serum or FCS for human lymphocytes and mouse lymphocytes, respectively. The infected lymphocytes were then incubated at 37°C in 5% CO2 for up to 4 days.
Assessment of Chlamydia infection by microscopy. After 1 to 4 days of incubation, the infected lymphocytes were centrifuged on a microscopic slide by a Cytospin (Shandon, Sewickley, Pa.). After fixing with ethanol, cells were stained with Chlamydia genus-specific FITC-conjugated monoclonal antibody (specific to Chlamydia lipopolysaccharide; Research Diagnostics, Flanders, N.J.). The presence of inclusion bodies in the sample was then determined with a fluorescence microscope. In some experiments, isolated mouse lymphocytes infected with C. pneumoniae were double stained with PE-conjugated anti-mouse CD3 antibody (BD Pharmingen) and FITC-conjugated anti-Chlamydia lipopolysaccharide (LPS) monoclonal antibody (Fitzgerald International Inc., Concord, Mass.). In brief, the cells on a microscopic slide were stained with anti-CD3 antibody and then treated with a Fix and Perm cell permeabilization kit (Caltag Laboratories, Burlingame, Calif.) with anti-Chlamydia antibody in accordance with the manufacture's protocol. The double-stained cells were then analyzed with a fluorescence microscope.
ELISA. Chlamydia LPS antigen in lymphocyte cultures was detected by an enzyme-linked immunosorbent assay (ELISA) kit (IDEIA PCE Chlamydia; Dako Ltd., Ely, United Kingdom). C. pneumoniae-infected lymphocytes (106 cells) were suspended in 1.0 ml of triethanolamine buffer and heated at 95°C for 15 min to extract Chlamydia LPS. The specimen (200 µl) containing Chlamydia LPS was then determined by sandwich ELISA using monoclonal anti-Chlamydia and alkaline phosphatase-conjugated anti-Chlamydia antibodies supplied in the kit. As a standard for Chlamydia LPS, a series of diluted EBs were spiked into the cell cultures and then Chlamydia LPS was extracted from the cultures. The relative number of Chlamydia organisms was calculated from the standard curve. The lower detection limit was 5 × 104 EBs/assay.
PCR. To detect C. pneumoniae-specific DNA, infected lymphocytes (106 cells) were collected at appropriate time points, and DNA was isolated using the QIAmp DNA minikit (Qiagen, Valencia, Calif.) in accordance with the manufacturer's manual. The PCR was performed with the Universal Amplification and Detection system (Intergen, Purchase, N.Y.) with primers specific for the C. pneumoniae major outer membrane protein gene (omp1) (14) in a Minicycler (MJ Research, Watertown, Mass.) in accordance with the manufacturer's manual. The first cycle, consisting of a 5-min degradation at 94°C, was followed by 50 cycles of 30 s at 94°C, 45 s at 50°C, and 1 min 30 s at 72°C, with a final extension for 10 min at 72°C. The PCR products were analyzed by a Fmax fluorometer (Molecular Devices, Sunnyvale, Calif.).
Electron microscopy. For transmission electron microscopy (TEM), after incubation the lymphocytes were immersed in a fixative containing 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) for 24 h at 4°C and then rinsed in 2.5% sucrose in 0.1 M phosphate buffer at pH 7.4. They were postfixed with 1% osmium tetroxide in 0.1 M phosphate (pH 7.4) at 4°C for 45 min. After a brief rinse in 2.5% sucrose, they were processed for alcohol dehydration and embedding in Epon 812 as described previously (19). Ultrathin sections of the cells were stained with lead citrate and uranium acetate before viewing on an electron microscope.
| |
RESULTS |
|---|
|
|
|---|
When either human or murine lymphocytes were infected with C. pneumoniae, centrifuged to remove free bacteria from the cells, and then incubated for up to 4 days, Chlamydia organisms obviously multiplied within the lymphocytes, as demonstrated by four methods: detection of inclusion bodies by staining with anti-Chlamydia monoclonal antibody conjugated with FITC in lymphocytes, stained with lymphocyte cell surface markers, demonstration of chlamydiae in lymphocytes by TEM, and detection of increased Chlamydia antigen by ELISA and of C. pneumoniae-specific DNA in the lymphocyte cultures by PCR at various times after infection.
Chlamydia inclusion body formation in
lymphocytes.
We initially determined whether human peripheral
blood lymphocytes isolated from a buffy coat are susceptible to in
vitro C. pneumonia infection. Lymphocytes obtained from
different donors were infected with Chlamydia EBs and
incubated in the presence of cycloheximide, which is a common method
for the enhancement of Chlamydia growth in cell cultures
(7), and then incubated further. At various time points
after infection, such as 0, 1, 2, 3, and 4 days, the cells were
harvested on a glass slide, fixed, and stained with genus-specific
anti-Chlamydia monoclonal antibody conjugated with FITC.
Figure 1A and B show representative
results that obvious Chlamydia inclusion bodies stained with
anti-Chlamydia antibody in a lymphocyte were evident 3 days
after infection. Wright staining of lymphocyte cultures showed that the
lymphocyte cultures used were highly purified, as determined by
morphology (more than 95% lymphocytes) (data not shown). However, it
is notable that the infection of lymphocytes obtained from individual
donor buffy coats with C. pneumoniae was positive for only 4 of 11 donors tested.
|
TEM analysis of infected lymphocytes.
In order to analyze in
detail the infection in a cell, C. pneumoniae-infected human
as well as mouse lymphocytes were examined by TEM. Figure
2 shows a representative electron
micrograph of chlamydiae attached to or in human peripheral blood
lymphocytes. At an early infection point, such as just after infection,
chlamydiae attached to the surface of a lymphocyte as well as
chlamydiae within the cytoplasm of the lymphocyte were observed (Fig.
2A and B). At a later time after infection, such as 3 days after infection, there were many but variably sized Chlamydia
particles (0.3 to 0.5 µm), including reticulate-like or intermediate
bodies, which were not as big as seen in HEp-2 cells, in the lymphocyte cytoplasm (Fig. 2C and D). The Chlamydia particles in an
inclusion body with membrane were also observed (data not shown).
Similar findings were noted in the mouse spleen lymphocytes after
infection with C. pneumoniae (data not shown).
|
Chlamydia antigen in infected lymphocytes.
To
measure the quantity of chlamydiae in infected lymphocytes, the amount
of Chlamydia LPS in mouse lymphocyte cultures was assessed
by ELISA, which has been established previously (20), at
different incubation time points after infection. The ELISA specific
for Chlamydia LPS could quantify Chlamydia
organisms in lymphocyte lysates of between 5 × 104 and 5 × 107
EBs/assay using the standard lymphocyte cultures spiked with Chlamydia EBs. As shown in Fig.
3, at the beginning of infection relatively few chlamydiae were recovered from the lymphocyte cultures. However, the relative number of Chlamydia organisms, which
was calculated from the LPS concentrations determined by ELISA, in the
cultures was increased during the infection and almost reached a
plateau at 3 to 4 days after infection due to increased dead lymphocytes (data not shown). As is obvious in Fig. 3, the relative number of Chlamydia organisms recovered from the cultures at
3 days after infection was significantly increased compared to the beginning of infection.
|
Increased C. pneumoniae-specific DNA in infected
lymphocytes.
Since analysis by both microscopy with
FITC-conjugated anti-Chlamydia antibody and the ELISA
specific for Chlamydia LPS was genus specific, not C. pneumoniae specific, C. pneumoniae-specific DNA in the
cultures was assessed by PCR with primers specific for C. pneumoniae omp1. The adjusted amount of extracted DNA (0.2 µg)
obtained from lymphocyte cultures at different time points was
subjected to PCR, and the PCR products were semiquantified. As shown in
Fig. 4, C. pneumoniae-specific
DNA in the lymphocyte cultures increased during infection similar to
that seen in the ELISA for Chlamydia LPS.
|
Infection of purified T lymphocytes with C. pneumoniae. In order to determine whether T lymphocytes are susceptible to Chlamydia infection, T-enriched lymphocyte cultures were prepared using a T-cell enrichment column with mouse spleen lymphocytes. The prepared T-cell fractions were more than 95% CD3 positive and had only trace numbers of CD19-positive cells, as determined by fluorescence-activated cell sorting (FACS) analysis. Growth of C. pneumoniae in the T-cell cultures was assessed by microscopy using FITC-conjugated anti-Chlamydia antibody to detect Chlamydia inclusion bodies (Fig. 1E and F). At the beginning of infection, only a chlamydiae were observed by fluorescence microscopy (Fig. 1E). In contrast, at 3 days after infection, the T-lymphocyte cultures showed an obvious increase in number and size of Chlamydia inclusion bodies in the cultures (Fig. 1F).
Infection of T-lymphocyte cell lines.
Since it is difficult to
prepare a 100% pure culture of lymphocytes with a primary culture of
lymphocytes, using an established T-lymphocyte cell line is another way
to demonstrate possible infection of lymphocytes with C. pneumoniae. In this regard, Molt 3 T-lymphocyte cells were used
for in vitro infection with C. pneumoniae. As shown in Fig.
5, the relative number of
Chlamydia organisms recovered from cultures infected with
viable bacteria was significantly increased during cultivation for 3 days. In contrast, UV-killed bacteria-treated cultures did not show any increase in bacteria during cultivation. The observations of
Chlamydia inclusions in the cells determined by microscopy
with FITC-conjugated anti-Chlamydia antibody were parallel
with the findings of the bacterial antigen analysis (Fig. 5).
|
| |
DISCUSSION |
|---|
|
|
|---|
Infection of host cells with C. pneumoniae may change a variety of host cell functions. For instance, when Chlamydia spp. infect monocytes, the infection inhibits host cell apoptosis due, at least partially, to interleukin-10 (IL-10) induction during the infection (6). Macrophage foam cells are inducible by Chlamydia infection by changing the uptake of lipids in infected macrophages (14, 15). A variety of proinflammatory cytokines are also induced from monocytes infected with C. pneumoniae (12, 17). These modulated host cell functions may play an important role in the development of the diseases associated with C. pneumoniae.
Lymphocytes are another major immune cell type besides macrophages in the development of chronic inflammatory diseases, including atherosclerosis. It is well documented that the lesions of atherosclerosis contain a focal accumulation of macrophages and T lymphocytes with the capacity to secret cytokines (2, 11, 24, 27, 28). This inflammatory response may result in plaque rupture and thrombosis, eventually causing stroke or myocardial infarction (30). Therefore, an immune response including regulation of inflammation by immune cells to C. pneumoniae may be critical for the development of atherosclerosis associated with C. pneumoniae. In this regard, if lymphocytes permit Chlamydia infection, involvement of infected lymphocytes in the development of atherosclerosis or other inflammatory diseases caused by C. pneumoniae infection may have a critical role in the pathogenesis of the diseases.
The demonstration of in vitro C. pneumoniae infection of lymphocytes in this study was achieved by several criteria, including morphology as well as demonstration of antigen and DNA levels. All of the criteria tested supported the conclusion that chlamydiae multiplied in lymphocyte cultures, which contained more than 95% lymphocytes, as determined by morphology. However, possible contamination with monocytes, which support the growth of chlamydiae, in the lymphocyte cultures was still a possibility, even though there was only a small number of monocytes. Therefore, the amount of Chlamydia antigen recovered from the lymphocyte cultures at the end of infection may be associated with some chlamydiae in monocytes, but this is unlikely because there were few monocytes in the cultures. On the other hand, the microscopic study clearly showed that lymphocytes defined by morphology as well as lymphocyte-specific surface molecules, such as CD3 for T lymphocytes, obviously had inclusion bodies, as determined with FITC-conjugated anti-Chlamydia monoclonal antibody.
The TEM analysis of infected lymphocytes supported the findings of fluorescence microscopy. In addition, it was demonstrated that purified T-lymphocyte cultures which showed a greater than 95% purity of CD3-positive cells allowed the growth of C. pneumoniae. Finally, demonstration of the growth of C. pneumoniae in the established T-lymphocyte cell line Molt 3 cultures supported the possible infection of lymphocytes with this bacterium. Thus, these findings indicate that C. pneumoniae can infect and multiply in lymphocytes, particularly T lymphocytes, in vitro.
Although we extensively examined propagation of the bacteria in lysates of lymphocytes using the HEp-2 cell culture system, which is considered the most conventional culture system for C. pneumoniae growth, only specimens obtained from the cells just after infection were positive. Similar results were obtained in the case of human peripheral blood monocytes and the human monocytic cell lines U937 and RAW. That is, the propagation of infected C. pneumoniae in the lysates of these cells was not successively detected (1, 4). Therefore, it can be conjectured that the adaptation of C. pneumoniae to host cells or immature EB formation in infected lymphocytes may have occurred.
It is notable that human peripheral lymphocytes did not always allow Chlamydia infection. The reason for the variation in the susceptibility to Chlamydia infection among lymphocytes obtained from different donors is not known. C. pneumoniae is one of the most common pathogens of humans, supported by the fact that the prevalence of antibodies to this bacterium increases with age and about 50% of the population has been infected with this organism by age 50 (9). Therefore, it seems likely that besides the genetic background, the immunological background of a donor may also affect the susceptibility of these lymphocytes to this organism. This speculation is at least partly supported by the results that mouse lymphocytes, which have the same genetic background and have not been infected with chlamydiae, showed a consistent susceptibility to in vitro Chlamydia infection.
The BALB/c mouse strain has been described as resistant for experimental C. pneumoniae infection (16), but the BALB/cAnN mouse strain shows susceptibility to Chlamydia infection (32). In addition, a recent study showed successful experimental C. pneumoniae infection in BALB/c mice (5). Thus, the susceptibility of the BALB/c mouse strain, which was used as a source for the lymphocyte preparation in this study, is not consistent with other reports because of the different experimental conditions between studies. Nevertheless, in vitro susceptibility of lymphocytes to Chlamydia infection may not be directly comparable with in vivo susceptibility due to the different complexities between the systems.
The frequency of inclusion body formation of each lymphocyte in the cultures was not high compared with HEp-2 cells, which are used for the propagation of Chlamydia spp., even though the infectivity ratio was similar between the two cultures (data not shown). The relatively low frequency of inclusion body formation in lymphocytes may be related to several reasons. One of the possible reasons is the use of lymphocyte mixtures, which consist of several subpopulations of lymphocytes, such as B and T cells. If only a particular lymphocyte subset is susceptible to Chlamydia infection, the frequency of Chlamydia infection of each lymphocyte in lymphocyte cultures may be limited. This possibility seems likely because purified T-lymphocyte cultures showed more frequent Chlamydia inclusion bodies after infection than nonpurified lymphocyte cultures (data not shown).
In vivo susceptibility of lymphocytes to chlamydiae during infection is not known. However, the finding of the Chlamydia DNA recovery from CD3+ peripheral blood leukocytes from patients (18) suggests that lymphocytes may serve as a host cell for chlamydiae in vivo. Furthermore, Moazed et al. reported that in experimental infection of mice with C. pneumoniae, it was demonstrated that the bacteria were spread via peripheral blood mononuclear cells, and the authors speculated that the responsive cell vehicle may be monocytes/macrophages (21). However, since the study did not fractionate the peripheral blood mononuclear cells to determine the cell vehicle for C. pneumoniae, it was not clear which peripheral blood mononuclear cells were responsible as the vehicle. Nevertheless, these reports support the possibility that lymphocytes may serve as a host cell in vivo.
The ultrastructural study of infected lymphocytes by TEM revealed that infected chlamydiae were located in the cytoplasm of the cell at the early phase of the infection. The overall shape of such Chlamydia particles observed in a lymphocyte was similar to the finding in HeLa cells (31), which showed a characteristic size and condensed nucleotide structure. In the late phase of infection, such as 3 days after infection, apparent growth of chlamydiae in a cell was observed. In contrast to the early phase of infection, many variable Chlamydia particle sizes, including reticulate-like bodies with a large periplasmic space, were seen in a cell. These ultrastructural findings of such variable sizes of Chlamydia particles in a cell were similar to our other observations in human monocytes (data not shown) as well as in a previous report utilizing human monocytes (1), except that there were relatively smaller numbers of Chlamydia particles in an inclusion. Thus, the overall morphology of Chlamydia particles in lymphocytes was nearly comparable to the previous report (1), with minor differences at the late phase of infection.
Positive Chlamydia infection of lymphocytes may impair lymphocyte functions, particularly cellular immunity, because T lymphocytes are a target for infection. However, no data are yet available as to how Chlamydia infection may impair or affect lymphocyte functions. Nevertheless, the evidence that C. pneumoniae can replicate in lymphocytes suggests that these cells may be an important host cell for dissemination of the organisms as well as possibly alter lymphocyte functions and certain immune mechanisms in an infected individual. Thus, the results presented in this study may provide a new direction for understanding C. pneumoniae infection and immunity.
| |
ACKNOWLEDGMENTS |
|---|
We thank Akira Matsumoto, Kawasaki Medical School, Kawasaki, Japan, for cooperation in training S.H. We also thank Raymond Widen, Tampa General Hospital, Tampa, Fla., for performance of the flow cytometric analysis.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, FL 33612. Phone: (813) 974-2332. Fax: (813) 974-4151. E-mail: yyamamot{at}hsc.usf.edu.
Editor: J. D. Clements
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Airenne, S.,
H. M. Surcel,
H. Alakärppä,
K. Laitinen,
J. Paavonen,
P. Saikku, and A. Laurila.
1999.
Chlamydia pneumoniae infection in human monocytes.
Infect. Immun.
67:1445-1449 |
| 2. | Emeson, E. E., and A. L. Robertson. 1988. T lymphocytes in aortic and coronary intimas: their potential role in atherogenesis. Am. J. Pathol. 135:369-376[Abstract]. |
| 3. | Fryer, R. H., M. L. Woods, and G. M. Rodgers. 1994. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J. Investig. Med. 45:168-174. |
| 4. | Gaydos, C. A., J. T. Summersgill, N. N. Sahney, J. A. Ramirez, and T. C. Quinn. 1996. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect. Immun. 64:1614-1620[Abstract]. |
| 5. |
Geng, Y.,
K. Berencsi,
Z. Gyulai,
T. Valyi-Nagy,
E. Gonczol, and G. Trinchieri.
2000.
Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection.
Infect. Immun.
68:2245-2253 |
| 6. |
Geng, Y.,
R. B. Shane,
K. Berencsi,
E. Gonczol,
M. H. Zaki,
D. J. Margolis,
G. Trinchieri, and A. H. Rook.
2000.
Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10.
J. Immunol.
164:5522-5529 |
| 7. | Godzik, K. L., E. R. O'Brien, S. K. Wang, and C. C. Kuo. 1995. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol. 33:2411-2414[Abstract]. |
| 8. | Gran, J. T., R. Hjetland, and A. H. Andreassen. 1993. Pneumonia, myocarditis and reactive arthritis due to Chlamydia pneumoniae. Scand. J. Rheumatol. 22:43-44[Medline]. |
| 9. | Grayston, J. T., L. A. Campbell, C. C. Kuo, C. H. Mordhorst, P. Saikku, D. H. Thom, and S.-P. Wang. 1990. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161:618-625[Medline]. |
| 10. | Hahn, D. L. 1992. Chlamydia pneumoniae infection and asthma. Lancet 339:1173-1174[Medline]. |
| 11. | Hansson, G. K., J. Holm, and L. Jonasson. 1989. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. 135:169-175[Abstract]. |
| 12. | Heinemann, M., M. Susa, U. Simnacher, R. Marre, and A. Essig. 1996. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect. Immun. 64:4872-4875[Abstract]. |
| 13. |
Jantos, C. A.,
R. Roggendorf,
F. N. Wuppermann, and J. H. Hagemann.
1998.
Rapid detection of Chlamydia pneumoniae by PCR-enzyme immunoassay.
J. Clin. Microbiol.
36:1890-1894 |
| 14. |
Kalayoglu, M. V., and G. I. Byrne.
1998.
Chlamydia pneumoniae component that induces macrophage foam cell formation is Chlamydial lipopolysaccharide.
Infect. Immun.
66:5067-5072 |
| 15. | Kalayoglu, M. V., and G. I. Byrne. 1998. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J. Infect. Dis. 177:725-729[Medline]. |
| 16. | Kaukoranta-Tolvanen, S. S., A. L. Laurila, P. Saikku, M. Leinonen, L. Liesirova, and K. Laitinen. 1993. Experimental infection of Chlamydia pneumoniae in mice. Microb. Pathog. 15:293-302[CrossRef][Medline]. |
| 17. | Kaukoranta-Tolvanen, S. S., T. Ronni, M. Leinonen, P. Saikku, and K. Laitinen. 1996. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb. Pathog. 21:407-411[CrossRef][Medline]. |
| 18. |
Kaul, R.,
J. Uphoff,
J. Wideman,
S. Yadlapalli, and W. M. Wenman.
2000.
Detection of Chlamydia pneumoniae DNA in CD3+ lymphocytes from healthy blood donors and patients with coronary artery disease.
Circulation
102:2341-2346 |
| 19. |
Klein, T. W.,
Y. Yamamoto,
H. K. Brown, and H. Friedman.
1991.
Interferon- induced resistance to Legionella pneumophila in susceptible A/J mouse macrophages.
J. Leukoc. Biol.
49:98-103[Abstract].
|
| 20. |
Miyashita, N., and A. Matsumoto.
1992.
Establishment of a particle-counting methof for purified elementary bodies of Chlamydia and evaluation of the IDEIA Chlamydia kit and DNA probe by using the purified elementary bodies.
J. Clin. Microbiol.
30:2911-2916 |
| 21. | Moazed, T. C., C. C. Kuo, J. T. Grayston, and L. E. Campbell. 1998. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J. Infect. Dis. 177:1322-1325[Medline]. |
| 22. |
Molestina, R. E.,
D. Dean,
R. D. Miller,
J. A. Ramirez, and J. T. Summersgill.
1998.
Characterization of a strain of Chlamydia pneumoniae isolated from a coronary atheroma by analysis of the omp1 gene and biological activity in human endothelial cells.
Infect. Immun.
66:1370-1376 |
| 23. | Muhlstein, J. B. 1998. Bacterial infections and atherosclerosis. J. Investig. Med. 46:396-402[Medline]. |
| 24. | Munro, J. M., J. D. van der Walt, C. S. Munro, J. A. Chalmers, and E. L. Cox. 1987. An immunohistochemical analysis of human aortic fatty streaks. Hum. Pathol. 18:375-380[Medline]. |
| 25. | Pechere, J.-C. 1996. In J.-C. Pechere (ed.), Intracellular bacterial infections. Cambridge Medical Publications, West Sussex, England. |
| 26. | Quinn, T. C., and C. A. Gaydos. 1999. In vitro infection and pathogenesis of Chlamydia pneumoniae in endovascular cells. Am. Heart J. 138:507-511[CrossRef][Medline]. |
| 27. | Ramshaw, A. L., and D. V. Parums. 1990. Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis. Histopathology 17:543-552[Medline]. |
| 28. |
Stemme, S.,
J. Holm, and G. K. Hansson.
1992.
T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1.
Arterioscler. Thromb.
12:206-211 |
| 29. | Summersgill, J. T., N. N. Shaney, C. A. Gaydos, T. C. Quinn, and J. A. Ramirez. 1995. Inhibition of Chlamydia pneumoniae growth in Hep-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. Infect. Immun. 63:2801-2803[Abstract]. |
| 30. | Uyemura, K., L. L. Demer, S. C. Castle, D. Jullien, J. A. Berliner, M. K. Gately, R. R. Warrier, N. Pham, A. M. Fogelman, and R. L. Modlin. 1996. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Investig. 97:2130-2138[Medline]. |
| 31. |
Wolf, K.,
E. Fisher, and T. Hackstadt.
2000.
Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells.
Infect. Immun.
68:2379-2385 |
| 32. |
Yang, Z. P.,
C. C. Kuo, and J. T. Grayston.
1993.
A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis.
Infect. Immun.
61:2037-2040 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|